Clinical Trial

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Recruiting
View on ClinicalTrials.gov →
Summary
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07332975
Lead Sponsor University of Pittsburgh
Conditions Triple Negative Breast Cancer
Enrollment 77 participants
Start Date 2026-01-20
Primary Completion 2029-01-20 (estimated)
Study Completion 2029-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-01